Discovery of a 1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity

Journal of Medicinal Chemistry

Volumn 48, Issue 18, 2005, Pages 5639-5643

  Wittman, Mark ^a   Carboni, Joan ^a   Attar, Ricardo ^a   Balasubramanian, Balu ^a   Balimane, Praveen ^a   Brassil, Patrick ^a   Beaulieu, Francis ^a   Chang, Chiehying ^a   Clarke, Wendy ^a   Dell, Janet ^a   Eummer, Jeffrey ^a   Frennesson, David ^a   Gottardis, Marco ^a   Greer, Ann ^a   Hansel, Steven ^a   Hurlburt, Warren ^a   Jacobson, Bruce ^a   Krishnananthan, Subramaniam ^a   Lee, Francis Y ^a   Li, Aixin ^a   Lin, Tai An ^a   Liu, Peiying ^a   Ouellet, Carl ^a   Sang, Xiaopeng ^a   Saulnier, Mark G ^a   Stoffan, Karen ^a   Sun, Yax ^a   Velaparthi, Upender ^a   Wong, Henry ^a   Yang, Zheng ^a   Zimmermann, Kurt ^a   Zoeckler, Mary ^a   Vyas, Dolatrai ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1H BENZOIMIDAZOL 2 YL 1H PYRIDIN 2 ONE; BMS 536924; GLUCOSE; INSULIN LIKE GROWTH FACTOR RECEPTOR KINASE INHIBITOR; INSULIN RECEPTOR; MACROGOL 400; PHOSPHOTRANSFERASE INHIBITOR; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; HAPLORHINI; HUMANS; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; PYRIDINES; PYRIDONES; RATS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 24744437999     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050392q     Document Type: Article

References (25)

1. Grothey, A.; Voigt, W.; Schober, C.; Muller, T.; Dempke, W.; Schmoll, H. J. The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J. Cancer Res. Clin. Oncol. 1999, 125, 166-173.
2. Vicentini, L. M.; Zhou, M.; Daly, R.; Myers, M. J., Jr.; Backer, J. M.; Ullrich, A.; White, M. F.; Schlessinger, J.; Skolnik, E. Y.; Lee, C. H.; Batzer, A. The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS-1 and She: implications for insulin control of ras signaling. EMBO J. 1993, 12, 1929-1936.
3. Vanhaesebroeck, B.; Alessi, D. R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 2000, 346, 561-576.
4. Ma, J.; Pollak, M. N.; Giovannucci, E.; Chan, J. M.; Tao, Y.; Hennekens, C. H.; Stampfer, M. J. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst. 1999, 91, 620-625.
5. (a) Hankinson, S. E.; Willett, W. C.; Colditz, G. A.; Hunter, D. J.; Michaud, D. S.; Deroo, B.; Rosner, B.; Speizer, F. E.; Pollak, M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351, 1393-1396.
6. (b) Martin, J. L. In Insulin-Like Growth Factors; LeRoith, D., Zumkeller, W., Baxter, R. C., Eds.; Landes Bioscience, Georgetown, TX, 2003; pp 367-384.
7. Chan, J. M.; Stampfer, M. J.; Giovannucci, E.; Gann, P. H.; Ma, J.; Wilkinson, P.; Hennekens, C. H.; Pollak, M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (Washington, D.C.), 1998, 279, 563-566.
8. Wolk, A.; Mantzoros, C. S.; Andersson, S. O.; Bergstrom, R.; Signorello, L. B.; Lagiou, P.; Adami, H. O.; Trichopoulos, D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer Inst. 1998, 90, 911-915.
9. Yu, H.; Spitz, M. R.; Mistry, J.; Gu, J.; Hong, W. K.; Wu, X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J. Natl. Cancer Inst. 1999, 91, 151-156.
10. Favelyukis, S.; Till, J. H.; Hubbard, S. R.; Miller, W. T. Nat. Struct. Biol. 2001, 8, 1058-1063.
11. Burtrum, D.; Zhu, Z.; Lu, D.; Anderson, D. M.; Prewett, M.; Pereira, D. S.; Bassi, R.; Abdullah, R.; Hooper, A. T.; Koo, H.; Jimenez, X.; Johnson, D.; Apblett, R.; Kussie, P.; Bohlen, P.; Witte, L.; Hicklin, D. J.; Ludwig, D. L. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 2003, 63, 8912-8921.
12. (a) Garcia-Echeverria, C.; Pearson, M. A.; Marti, A.; Meyer, T.; Mestan, J.; Zimmermann, J.; Gao, J.; Brueggen, J.; Capraro, H. G.; Cozens, R.; Evans, D. B.; Fabbro, D.; Furet, P.; Porta, D. G.; Liebetanz, J.; Martiny-Baron, G.; Ruetz, S.; Hofmann, F. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-1R kinase. Cancer Cell 2004, 5, 231-239.
13. (b) Mitsiades, C. S.; Mitsiades, N. S.; McMullan, C. J.; Poulaki, V.; Shringarpure, R.; Akiyama, M.; Hideshima, T.; Chauhan, D.; Joseph, M.; Libermann, T. A.; Garcia-Echeverria, C.; Pearson, M. A.; Hofmann, F.; Anderson, K. C.; Kung, A. L. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004, 5, 221-230.
14. Blum, G.; Gazit, A.; Levitzki, A. Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J. Biol. Chem. 2003, 278, 40442-40454.
15. Girnita, A.; Girnita, L.; del Prete, F.; Bartolazzi, A.; Larsson, O.; Axelson, M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 2004, 64, 236-242.
16. Fang, F. G.; Xie, S.; Lowery, M. W. Catalytic enantioselective synthesis of 20(S)-camptothecin: A practical application of the sharpless asymmetric dihydroxylation reaction. J. Org. Chem., 1994, 59, 6142-6143.
17. Oral exposure was determined using a coarse pharmacokinetics screen. Screening was accomplished by dosing three mice per group with 20 mg/kg in 80:20 PEG400/water (v/v). Serum concentrations were determined at 30 min, 1 h, and 4 h.
18. Carboni, J. M.; Lee, A. V.; Hadsell, D. L., Rowley, B. R.; Lee, F. Y.; Bol, D. K.; Camuso, A. E.; Gottardis, M.; Greer, A. F.; Ho, C. P.; Hurlburt, W.; Li, A.; Saulnier, M.; Velaparthi, U.; Wang, C.; Wen, M.-L.; Westhouse, R. A.; Wittman, M.; Zimmermann, K.; Rupnow, B. A., Wong, T. W. Tumor development by transgenic expression of a constitutively active insulin-like growth factor-1 receptor. Can. Res. 2005, 65, 3781-3787.
19. (a) Kalebic, T.; Tsokos, M.; Helman, L. J. In vivo treatment with antibody against IGF-I receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res. 1994, 54, 5531-5534.
20. (b) Navid, F.; Helman, L. J. In Insulin-Like Growth Factors; LeRoith, D., Zumkeller, W., Baxter, R. C., Eds.; Landes Bioscience, Georgetown, TX, 2003; pp 390-398.
21. Tai-An, L. A more complete discussion will be presented in a manuscript to be submitted. Compound 3 does not have a direct effect on MAPK or Akt (see Table 2). In some cells lines where proliferation could be inhibited at <1μM, no evidence of MAPK inhibition was observed, suggesting that MEK inhibition is not a significant contributor to the activity observed in vitro or in vivo.
22. Garofalo, R. S.; Orena, S. J.; Rafidi, K.; Torchia, A. J.; Stock, J. L.; Hildebrandt, A. L.; Coskran, T.; Black, S. C.; Brees, D. J.; Wicks, J. R.; McNeish, J. D.; Coleman, K. G. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBB. J. Clin. Invest. 2003, 112, 197-208.
23. Marcoux, J.-F.; Wagaw, S.; Buchwald, S. L. Palladium-catalyzed amination of aryl bromide: Use of phosphinoether ligands for the efficient coupling of acyclic secondary amines. J. Org. Chem. 1997, 62, 1568-1569.
24. Devocelle, M.; Mortreux, A.; Agbossou, F.; Dormoy, J.-R. Alternative synthesis of the chiral atypical β-adrenergic phenylethanolaminotetraline agonist SR58611A using enantioselective hydrogenation. Tetrahedron Lett. 1999, 40, 4551-4554. A modifled procedure was used in which methanol was added to greatly enhance the yield of the desired α-chloroketone.
25. Corey, E. J.; Shibata, S.; Bakshi, R. K. An efficient and catalytically enantioselective route to (S)-(-)-phenyloxirane. J. Org. Chem. 1988, 53, 2861-2863.